Pfizer Inc. $PFE is Huber Capital Management LLC’s 7th Largest Position

Huber Capital Management LLC grew its stake in Pfizer Inc. (NYSE:PFE) by 5.9% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 813,518 shares of the biopharmaceutical company’s stock after purchasing an additional 45,000 shares during the quarter. Pfizer makes up 3.3% of Huber Capital Management LLC’s holdings, making the stock its 7th biggest position. Huber Capital Management LLC’s holdings in Pfizer were worth $20,728,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also modified their holdings of the company. Norges Bank purchased a new stake in shares of Pfizer in the 2nd quarter valued at approximately $2,270,157,000. Vanguard Group Inc. raised its position in Pfizer by 1.9% in the second quarter. Vanguard Group Inc. now owns 533,363,457 shares of the biopharmaceutical company’s stock valued at $12,928,730,000 after purchasing an additional 10,198,330 shares during the period. Franklin Resources Inc. boosted its position in shares of Pfizer by 47.8% during the third quarter. Franklin Resources Inc. now owns 25,070,148 shares of the biopharmaceutical company’s stock worth $638,787,000 after buying an additional 8,108,887 shares during the period. Neuberger Berman Group LLC boosted its holdings in shares of Pfizer by 203.8% in the 3rd quarter. Neuberger Berman Group LLC now owns 9,012,811 shares of the biopharmaceutical company’s stock valued at $229,346,000 after buying an additional 6,045,763 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership raised its stake in Pfizer by 43.4% during the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 18,718,955 shares of the biopharmaceutical company’s stock worth $453,747,000 after acquiring an additional 5,662,309 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of analysts recently commented on PFE shares. Weiss Ratings reissued a “hold (c-)” rating on shares of Pfizer in a report on Thursday, January 22nd. Guggenheim reissued a “buy” rating on shares of Pfizer in a research report on Wednesday, December 17th. Argus upgraded Pfizer from a “hold” rating to a “buy” rating and set a $35.00 target price on the stock in a report on Monday, March 2nd. Barclays assumed coverage on shares of Pfizer in a report on Thursday, February 19th. They set an “underweight” rating and a $25.00 target price on the stock. Finally, Cantor Fitzgerald restated a “neutral” rating and set a $27.00 price objective on shares of Pfizer in a research note on Wednesday, February 4th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, fourteen have given a Hold rating and three have given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $28.05.

Pfizer Price Performance

Shares of Pfizer stock traded up $0.11 on Friday, hitting $26.97. The company had a trading volume of 2,403,469 shares, compared to its average volume of 46,102,480. The company has a market cap of $153.34 billion, a PE ratio of 19.85 and a beta of 0.47. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.16 and a quick ratio of 0.87. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $27.94. The business has a 50-day simple moving average of $26.47 and a 200-day simple moving average of $25.51.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share for the quarter, beating analysts’ consensus estimates of $0.57 by $0.09. The company had revenue of $17.56 billion during the quarter, compared to the consensus estimate of $16.93 billion. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. Pfizer’s revenue was down 1.2% on a year-over-year basis. During the same period in the prior year, the company earned $0.63 EPS. Research analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Trending Headlines about Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: China approved Pfizer’s GLP‑1 weight‑management drug Xianweiying, opening a large market and adding a growth avenue beyond COVID products. Pfizer’s Weight Management Drug Wins China Approval
• Positive Sentiment: Early Phase‑2 data for trispecific antibody tilrekimig showed meaningful eczema improvement with a favorable safety profile — a successful later‑stage outcome could materially expand Pfizer’s immunology franchise. How Tilrekimig’s Trispecific Eczema Data At Pfizer (PFE) Has Changed Its Investment Story
• Positive Sentiment: Pfizer launched a new early‑stage oncology trial for PF‑07994525, extending its cancer pipeline and showing continued R&D investment that could produce longer‑term revenue drivers. Pfizer Advances Early‑Stage Cancer Candidate PF‑07994525
• Positive Sentiment: Completed Phase‑2 toddler study for Pfizer’s next‑gen pneumococcal vaccine advances that program toward later‑stage trials and potential label expansion. Pfizer Advances Next‑Gen Pneumococcal Vaccine
• Positive Sentiment: Scotiabank reiterated a Buy rating on Pfizer, which may support investor confidence and act as a near‑term positive catalyst for the stock. Scotiabank Sticks to Their Buy Rating for Pfizer (PFE)
• Neutral Sentiment: Analyst/outlet coverage highlights Pfizer’s high dividend yield (~6.5%) and deep discount from prior highs, framing the stock as an income/value play for long‑term investors. 1 Magnificent Dividend Stock Down 57% to Buy and Hold Forever
• Neutral Sentiment: Industry coverage and commentary (health‑care roundups) mention Pfizer alongside peers — useful context but not an immediate stock mover. Health Care Roundup: Market Talk
• Neutral Sentiment: Pfizer commentary on navigating regulatory uncertainty (company expert piece) underlines the firm’s focus on compliance but has limited immediate market impact. Be nimble, be ready: how to tackle regulatory uncertainty in clinical trials
• Negative Sentiment: Market reports show Pfizer’s share price dipped more than the broader market in recent sessions, reflecting short‑term selling pressure and investor caution. Pfizer (PFE) Sees a More Significant Dip Than Broader Market
• Negative Sentiment: Duplicate market‑movement coverage highlights the intraday weakness and may reinforce momentum selling. Pfizer (PFE) Sees a More Significant Dip Than Broader Market: Some Facts to Know
• Negative Sentiment: Competitive pressure: Bristol Myers’ deep late‑stage pipeline coverage reminds investors that peer advancements could divert future market share and investor attention away from Pfizer’s franchises. Is Bristol Myers’ Deep Pipeline the Key to Future Growth?

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.